Malignant disease in childhood : the price of cure : late physical and socioeconomic effects of treatment by Attard Montalto, Simon et al.
l 
Maltese Medical Journal. 1997; 9(2):20 
All rights reserved 
Malignant disease in childhood: The price of cure 

Late physical and socioeconomic effects of treatment 
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ABSTRACT: The aim of cancer therapy in childhood is to achieve a lasting cure without physical 
and psychosocial harm and, preferably, at a low financial cost. Although cure is possible in many 
types of childhood cancer, this is often accompanied by complications as a consequence of intensive 
therapy. These late effects primarily affect fertility, the cardio-respiratory and endocrinological 
systems. Psychosocial adverse effects may have serious implications on the marriage and 
employment prospects of those patients surviving into adulthood. Furthermore, the risk of 
treatment-induced, secondary malignancies may increase as survival improves. With current 
intensive chemotherapy and radiotherapy, the attainment of cure rates in excess of 60-70% is, 
inevitably, associated with significant morbidity. Indeed, recent developments in cancer therapy 
have focused on ways of reducing this morbidity, whilst still maintaining the overall improvement 
in survival. 
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Introduction 
Long term cure, as opposed JO short or medium-term 
survival, is presently a reality in up to 60% of children 
with malignant disease 1.2. Currently, 1 in 2,000 twenty 
year olds is a survivor of childhood cancer and this 
figure is estimated to climb to 1 in 1,000 by the early 
part of the 21 st century 1. The improved prognosis for 
many children with cancer has followed intensive 
clinical, pharn1acological and molecular biological 
research spanning the past thirty years. This research, 
administered via controlled, internationally co-ordinated 
trials, has resulted in significant improvements in 
paediatric cancer therapy. Nevertheless, the reality of a 
cure has been achieved with an increase in treatment­
related morbidity, both in the acute phase of therapy as 
well as long tern1. This paper reviews the late physical 
and psychological effects of current therapy for 
childhood cancer, and highlights the financial 
implications of achieving a cure for cancer. 
Late effects of cancer and cancer therapy 
As patients live longer, more late' effects are 
recognised, some of which predominantly involve 
specific systems (Table 1) whereas others are still poorly 
defined (e.g. libido, employment). Individual late effects 
may follow chemotherapy, radiotherapy and surgery. 
Cardiovascular sequelae 
Anthracyclines (e.g. doxorubicin, daunorubicin) are 
important agents in commonly used chemotherapeutic 
protocols for childhood leukaemia and solid tumours. 
Yet they are well recognised cardiotoxic agents, the 
toxicity increasing with cumulative dose and rapidity of 
Table 1 - Systems involved in late effects of 
childhood cancer 
Commonly affected Rarely affected III dejined 
cardiovascular gastroinleslinal neurological 
endocrine respiratory psychological 
reproductive special senses socioeconomic 
musculoskeletal renal secondary­
malignancy 
their infusion3. They usually result in a cardiomyopathy 
which may improve on discontinuation of the drug (with 
the risk of a diminished anti-cancer effect), but which 
can result in intractable heart failure 4 requiring 
transplantation (observation). Sudden cardiac 
decompensation may be precipitated by pregnancy, 
infection and strenuous exercise, even in those thought 
to have normal cardiac function . Indeed , all patients who 
have received anthracyclines should be carefully 
monitored during pregnancy. Arrhythmias, usually with 
a prolonged Q-T interval and supraventricular ectopics , 
are less common, but may result in sudden death 5. 
Radiotherapy at a dose >30Gy to the mediastinum 
involving the heart may exacerbate functional valvular 
dysfunction, predispose to premature coronary disease 
and increase the risk of infarction in later life 6. 
Radiotoxicity, like chemotoxicity, is also dose related. 
These sequelae have altered paediatric oncology 
practice such that the total dose of anthracycIines is 
carefully recorded and infusion times increased to 4-6 
hours from bolus injections. Their complete omission is 
likely to result in a significant risk of relapse, and current 
work is focusing on the simultaneous administration of 
cardioprotective agents 7. However, these expensive 
agents may reduce the efficacy of anthracycIines 7 and, 
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together with routine cardiac assessments with ECG and 
echocardiography, will increase the financial cost of 
treatment. The role of additional radionuclide functional 
cardiac scans is unclear but would further escalate the 
cost of follow up. 
Respiratory sequelae 
Complications of cancer therapy involving the lungs 
are unusual. Pulmonary fibrosis may develop following 
bleomycin and high dose radiotherapy (>30Gy), whereas 
whole lung irradiation results in small volume lungs with 
normal gas diffusion 8. The latter is associated with a 
mild to moderate decrease in exercise tolerance, in 
contrast to the severe handicap manifest by patients who 
develop pulmonary graft versus host disease (GYHD) 
after allogenic bone marrow transplantation or donor 
lymphocyte infusion for relapsed leukaemia 
(observation). Modern treatment protocols with 
restricted use of lung radiotherapy for widespread 
metastases in' refractory Wilms' tumour, and aggressive 
immuno-suppression against GYHD have reduced the 
incidence of these debilitating pulmonary sequelae. 
Nevertheless, total body irradiation (TBI) has a 
deleterious effect on alveolar growth and, when 
administered to young children prior to bone marrow 
transplantation, can result in pulmonary hypoplasia after 
a number of years. 
Endocrine sequelae 
Intensive chemotherapy and radiotherapy result in 
major late complications involving linear growth, 
pubertal development, fertility and thyroid function. 
These sequelae are particularly severe in those who 
receive combination therapy, especially involving 
allogenic bone marrow transplantation (Table 2) 9. 
Table 2: Endocrine sequelae after allogenic bone 
marrow transplantation (BMT) 
Sequelae 	 Indication for BMT 
Non malignant Malignancy 
survival 80% 20-70% 
growth 	 normal impaired 
hypothyroidism 
- compensated 	 8% 18-35% 
- overt <2% 8-11% 
thyroid neoplasia 0% 1.7% 
puberty, menarche normal delayed 
ovarian dysfunction <5% 20% 
azoospermia 50% 100% 
Leydig cell function normal impaired 
Effects on growth 
Hypopituitarism is common after surgery for 
hypothalamic tumours, and after radiotherapy for cranial 
tumours and CNS-directed treatment for leukaemia. The 
anterior pituitary is primarily affected, usually resulting 
in growth hormone (GH) deficiency and short stature. 
The precise mechanism of GH insufficiency following 
cranial radiotherapy is unclear but may be related to a 
reduction in GH-releasing hormone (somatostatin), 
which is associated with disorganised G H secretion and 
low amplitude GH peaks . The latter is exaggerated at 
puberty , when the normal surge in GH release does not 
occur. Indeed, 100% of patients who recei ved 30Gy 
involving the pituitary are GH deficient five years later. 
The damage and, therefore , subsequent loss in final 
height , is dose related 10 and more severe in young 
patients 11.12, especially those irradiated for a brain 
tumour rather than leukaemia 13 . GH deficiency is 
generally isolated and develops within two to fi ve years 
after treatment. Panhypopituitarism is less common, with 
deficiencies in TSH, gonadotrophin releasing hormone 
and lastly ACTH presenting over a period of several 
years . 
Chemotherapy not only exacerbates GH deficiency 
after radiotherapy but , in isolation, has been shown to 
reduce more than ISD in height in 32% of patients at 
one year, and up to 71% at six years 14 This effect may 
be due to the adverse effect of intensi ve chemotherapy 
on the growth plate 14.15, which is supported by in vivo 
observations but, as yet, remains unclear during in vitro 
studies. 
Once confirmed, growth hormone deficiency requires 
GH replacement by subcutaneous injection, approx­
imately five to seven times a week. GH may prevent 
further height loss but the final height achieved may still 
be suboptimal since GH may be less effective in patients 
who also have truncal shortening due to spinal 
irradiation 16 The loss in spinal growth is worse in 
younger patients and may be as much as lJcm with 
irradiation at one year versus 5.5cl11 at ten years 16 
Furthermore, treatment with a growth-promoting . 
potentially mutagenic, agent such as GH may increase 
the risk of second malignancies 17.18. 
Careful radiotherapy planning . ,md accurate targeting , 
if necessary under daily general anaesthesia, may help 
reduce pituitary damage. In patients 'at risk', GH 
replacement should be anticipated, and confilllled by 
suitable GH-provocation tests. In order to reduce the risk 
of second leukaemias, GH treatment is not commenced 
until two years have elapsed from the initial cancer 
treatment. 
Growth can also be adversely affected by direct 
radiation damage to bone, malnutrition , steroid therapy 
and, in children who received an allogenic bone marrow 
transplant, by graft versus host disease. 
Effects on puberty 
Precocious puberty is common, especially in girls who 
received cranial radiotherapy at a young age 19. This 
results in early closure of the epiphyses 12 and, together 
with blunting of the nomlal surge in GH during puberty, 
further exacerbates the problem of short stature 20 . 
Unless growth during puberty is closely monitored, an 
initial but inadequate growth spurt may mask underlying 
poor growth velocity . Once impending short stature is 
realised. treatment with GH must commence before 
menarche is established. Nevertheless, GH may be less 
effective in these patients unless combined with a 
gonadotrophin-releasing hormone analogue in order to 
arrest pubertal maturation. 
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Effects on reproduction 
Infertility in male survivors is common since several 
chemotherapeutic agents disrupt the -gernlinal epi­
thelium, resulting in small testes and azoospemlia 21.22. 
This damage is dose dependent, particularly with 
alkylating agents (e.g. cyclophosphamide), and 
especially when multiple chemotherapeutic agents are 
administered to younger boys 12.22.23. Leydig cell 
function. on the other hand, is rarely compromised and 
in 96% of cases, androgen replacement is not necessary23. 
In girls, the ovary is relatively chemotherapy-resistant 
and ovarian steroidogenesis is generally preserved 15.24. 
Although Inhibition of follicular maturation may result 
in premature menopause, the prospects for fertility are 
good. In a study of 40 girls treated for ALL, all 
progressed through puberty, 37 had normal menses and 9 
gave birth to 14 children without congenital anomalies or 
malignant disease 24. 
Radiotherapy administered directly to the testes causes 
germ cell ablation, fibrosis, azoospemlia and infertility. 
as well as impaired Leydig cell function requiring 
androgen replacement 25. The testes remain infantile in 
size 21, but the effect on libido remains difficult to 
quantify 21 -23. The LD50 of the human oocyte is <4cGy 
and ovarian radiotherapy causes a net loss of oocytes and 
impaired oestradiol production, resulting in delayed/ 
arrested puberty, amenorrhoea and infertility 26 
Oestrogen replacement is necessary to maintain 
secondary sexual characteristics, prevent osteoporosis 
and decrease the risk of ischaemic heart disease . 
Involvement of the uterus in the radiotherapy field 
disrupts its growth with a poor reproductive outcome. 
Indeed, these patients have an increased risk of mid­
trimester miscarriage, premature delivery and low birth 
weight infants. Furthermore, they are not suitable 
candidates for in-vitro fertilisation with donor oocytes 
since the uterus does not produce a satisfactory 
endometrial response to sex steroid replacement 26. 
Patients with a history of intensive chemotherapy and/ 
or pelvic or scrotal radiotherapy require regular clinical 
assessment of sexual maturation, together with 
measurements of FSH, LH, testosterone and oestradiol. 
A blunted response to human chorionic gonadotrophin 
stimulation will confirm gonadal hormonal failure and 
prompt androgen/oestrogen replacement. Male infertility 
is confirmed by azoospermia on semen analysis. 
Pretreatment spernl banking (at diagnosis) often 
produces a poor yield and is not widely available. In 
view of the serious psychosocial consequences of 
infertility, all affected patients should be offered 
professional counselling. Reassurance can be offered to 
those who had cancer in childhood and who retain 
fertili ty, since there is no increased risk of tteatment­
induced congenital anomalies or cancer in their 
offspring27 . 
Effects on thyroid function 
Although the precise impact of chemotherapy on the 
thyroid gland is unclear, its extreme susceptibility to 
radiotherapy is unequivocal. Thyroid dysfunction 
including hypothyroidism compensated by a high TSH 
drive, may develop within 12 months from 
radiotherapy28. Overt hypothyroidism usually develops 
in 66% of patients within three to six years of thyroid 
irradiation28.2'1. Earlier onset is observed in younger 
children and is proportional to increasing doses . 
Radiotherapy Increases the risk of morphological 
abnormalities such as focal hyperplasia, thyroiditis. 
thyroid fibrosis and adenomas. The" risk of carcinoma 
increases LOO-fold, and occurs in up to 1.7% of survi vors 
of cervical Hodgkins disease of the neck 2'1 . The risk is 
increased further in those with elevated TSH levels 
which persist for several years 29.30. Thyroid carcinomas 
have been reported after a prolonged latency period (> 13 
yrs) and, in this setting, are invariably fatal. Hence, long 
teml monitoring of TSH levels, thyroid ultrasound and 
isotope scans are indicated. Thyroxine replacement 
should be given to children with frank hypothyroidism. 
as well as to those with compensated thyroid dysfunction 
with the aim of returning elevated TSH levels to normal, 
thereby reducing the risk of thyroid carcinoma 2.30. 
Renal sequelae 
Decreased glomerular and tubular function follow high 
dose ifosfamide and cisplatinum 3IJ2 Renal 
dysfunction is exacerbated by anlinoglycoside 
antibiotics, but recovery is usually complete in the 
majority of patients. Without the concurrent use of 
mesna, alkylating agents (cyclophosphamide. 
ifosfamide) can result in haemorrhagic cystitis leading to 
fibrosis and reduced bladder capacity. 
Neurological sequelae 
Cranial irradiation, especially to the developing brain 
before the age of two years, is associated with neuronal 
damage and, often subtle, neurodisabilities. Significant 
memory deficit may follow treatment for ALL 33 and the 
IQ may be decreased by as much as five to ten points 
following cranial irradiation 34 Neuropsychometric 
deficit is usually greater with attention span and non 
verbal, cognitive skills so that these children have 
difficulty predominantly with mathematics and spelling. 
Given the slow rate of neuronal development, many of 
these effects are not manifest for several years. Indeed. 
the long term prospects for dementia as a result of 
irradiation-induced neurovascular damage In early 
childhood remains unknown . 
Other physical sequelae 
Hepatic fibrosis and veno-occlusive disease may 
follow the use of 6-mercaptopurine and busulphan . 
respectively. Auditory impairment IS common In 
survivors of childhood cancer, often as ,a direct 
chemotoxic effect (e.g. cisplatinum), or secondary to 
ototoxic antibiotics (aminoglycosides). Visual 
impairment follows unilateral enucleation which is 
necessary in 50% of patients with retinoblastoma, or is 
secondary to global atrophy and cataract formation after 
radiotherapy. Asymmetrical atrophy of the face, trunk or 
limbs is a significant, permanent problem after wide 
field, intensive radiotherapy (e.g. for sarcomas), whereas 
gross disfigurement follows surgical amputation. 
The use of mutagenic treatment modalities in 
susceptible individuals has led to an increasing number 
of reports of late secondary tumours 35 . These include 
radiotherapy-induced thyroid carcinoma and sarcomas in 
the peripheral area of radiotherapy fields, as well as 
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alkylating agent and etoposide-induced acute myeloid 
leukaemia. The risk of treatment-resistance in these 
secondary tumours is high, and they are invariably fatal. 
Psychological and psychosocial sequelae 
Although some families 'pull together' during a crisis, 
others may fall apart under the strain associated with a 
child with cancer. In this setting, behavioural problems 
in siblings as well as the patient, marital dysharmony and 
family breakdown, are not uncommon. 
Not surprisingly, children who survive childhood 
cancer may carry feelings of anger (why me?), 
resentment (why not someone else?), guilt and 
frustration into adulthood. These, coupled with the 
metabolic complications, physical handicaps and 
reproductive deficiencies highlighted above, may result 
in poor self esteem and, at times, psychiatric illness 
including depression I.2 . A poor ability to cope in 
society, rejection by peers, and diminished intellect will 
decrease the prospects for higher education. Ultimately 
the combination of physical and psychosocial problems 
dampen both the marital and job prospects of these 
patients. Indeed, in certain countries, some institutions 
(e.g. the armed forces) apply positive discrimination 
against their employment. Insurance may be a major 
problem - often it is simply not available or only offered 
at an extoitionate premium. 
Quality of life 
Attempts have been made to quantify 'quality of life' of 
survivors of cancer 36, but such assessments are highly 
subjective and, at best, extremely crude. Most 
questionnaire-based surveys are able to gauge physical 
problems rather better than psychosocial 'handicaps '. 
Nevertheless, reports would suggest that, once children 
survive their malignant condition, their quality of life is 
no worse than their peers 36.37 . 
Monetary costs of treatment 

Cost of acute treatment 

Assuming treatment is completed with no untoward 
complications or excessive admissions, an estimate for a 
single child weighing 15kg with acute lymphoblastic 
leukaemia being treated on the current chemotherapeutic 
protocol is approximately Lm5,OOO over 2.5 years (Table 
3). The cost may be two to three times' as much for those 
with solid tumours who may receive more intensive 
regimens (Table 3). With a mean of ten new and 
relapsed patients per year, this translates into an 
approximate annual expenditure of Lm50,000. Many of 
these patients are referred to hospitals in the UK with 
whom the Department operates a shared care 
programme, in order to complete treatment not available 
in Malta (e.g . bone marrow transplantation). If not for a 
reciprocal health care agreement between the two 
countries, these additional courses could inflate the 
annual cost to the Department of Health by two to three 
times, or more. 
Follow up costs 
To the 'acute' cost must be added imponderables such 
Table 3 - Monetary cost for treatment of childhood 
ALL and neuroblastoma 
Cost in Lm * ALL neuroblastoma 
per patient (l5kg) 
Days in hospital 3,680 5,600 
Drugs - cytotoxics 697 365 
- antibiotics 194 484 
- antiemetics 197 328 
Investigation 
- blood 120 180 
- imaging 50 250 
Procedures 
- cen tral line 49 49 
- surgery 0 1,000** * 
- transplant 0 ** 2,500 ** * 
TOTAL 4,987 10,756 
* Costs are calculated on current prices pertaining to 
government services. July 1997. 
** The estimate is for children with acute Iymphohlastic 
leukaemia (ALL) in first remission, when hone marrow 
transplalllation is not indicated. 
*** These estimates apply to treatment fiJl' neurohlastomu, 
which may include visits to the UK fiJl' surgery and pcripheml 
stem cell or autologous marrow transpluntation. 
as the cost of follow-up, subsequent cardiac, endocrine 
and other investigations, and treatment of late effects. As 
discussed previously, the latter may not be 
inconsequential: e.g . the annual cost of GH replacement 
is approximately Lm 1 ,000 per patient. Assisted fertility 
procedures may become standard treatment for these 
patients, but it is rather more difficult to provide for the 
unexpected, e.g. heart transplantation for those with 
intractable anthracycline-induced cardiomyopathy. 
Physicians have a duty to offer the 'best available' 
treatment and, at the outset, must inform parents of the 
late consequences of therapy. At diagnosis, the latter 
appear of little importance when compared with the 
chance of survival, but may invoke feelings of anger and 
guilt as years go by and the complications of treatment 
evolve. This raises the possibility of litigation 
proceedings against the health authorities by affected 
patients, a scenario that has become a reality in the 
United States, but not yet in Europe I . 
Measures to reduce late effects 
Clearly, prevention is better than cure. Continuously 
improved drug regimens, dosage, and scheduling, 
refined radiotherapy and surgical techniques all 
contribute toward lowering the morbidity of cancer 
therapy. Specific protective agents (e.g. against 
anthracycline-cardiomyopathy) may become available 
during the acute phase of treatment. Nevertheless, late 
complications are inevitable and need to be anticipated 
in survivors. Once confirmed, prompt correction will 
reduce further long term morbidity. Finally, quality of 
life is further enhanced by improved aids (e.g. 
prostheses), and a better understanding of the problems 
facing these patients both by the physicians involved in 
their care, as well as by the general population . . 
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Conclusion 
Major advances in cancer treatment in childhood have 
resulted in an overall cure rate of approximately 60% of 
cases 38. There is little doubt that the vast majority of 
childhood cancer should be treated. Management should 
entail modem chemotherapeutic regimens in order to 
effect the best chance of survival, with provision to 
anticipate and cater for treatment-induced early and late 
com·plications. The impact of late morbidity has been 
appreciated relatively recently , and unknown problems 
---., 	 may yet arise. Hence, the reduction of late effects has 
become a major goal in cancer treatment, equalling 
efforts to improve overall survival. 
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